SPECTRA OPTIA 10225

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional,l report with the FDA on 2020-03-13 for SPECTRA OPTIA 10225 manufactured by Terumo Bct.

Event Text Entries

[188487253] Lot number and expiry information are not available at this time. Investigation: patient had no past medical history. Patient was hospitalized for 3 months following myasthenia crisis, with chronic respiratory failure requiring tracheotomy and mechanical ventilatory support. The management of this refractory myasthenia was based on acetylcholinesterase inhibitors, corticosteroids, rituximab, and thymectomy. After a new relapse, daily tpes were started, with 4% albumin as the replacement fluid, which had a sodium concentration of 148 mmol/l and chloride concentration of 145 mmol/l. After the second saily tpe, the patient had a hyperchloremic metabolic acidosis reaction, so every other day tpes were started. Subsequent exchanges were spaced (every other day) and performed with less volume (1. 2 plasma volume). Laboratory tests performed after the next exchange showed an elevation of chloride at 110 mmol/l, but without significant acidosis. The analysis of substitution 4% albumin solution revealed a sodium concentration of 148 mmol/l and chloride concentration of 145 mmol/l. This acidosis is due to a reduction of the strong anion gap by an excessive rise of plasma chloride as well as a disproportionate renal bicarbonate elimination. Article citation: ritzenthaler, t. , grousson, s. , and dailler, f. Hyperchloremic metabolic acidosis following plasma exchange during myasthenia gravis crisis. Journal of clinical apheresis 31:479? 480 (2016). Published online 22 september 2015 in wiley online library (wileyonlinelibrary. Com). Investigation is in process. A follow-up report will be provided.
Patient Sequence No: 1, Text Type: N, H10


[188487254] Per an article in journal of clinical apheresis, a myasthenia gravis patient was started on every-other-day therapeutic exchange procedures (tpe) following a hyperchloremic metabolic acidosis reaction on daily tpes. Laboratory tests performed after the next exchange showed an elevation of chloride at 110 mmol/l, but without significant acidosis. Is unknown at this time if medical intervention was required for the elevated chloride level. The disposable set is not available for return because it was discarded by the customer. This product is not available within the us, but this report is being filed due to an alleged failure that could occur on a similarly marketed device platform cleared for use by the fda.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number1722028-2020-00113
MDR Report Key9830930
Report SourceFOREIGN,HEALTH PROFESSIONAL,L
Date Received2020-03-13
Date of Report2020-03-13
Date of Event2015-01-01
Date Mfgr Received2020-02-17
Date Added to Maude2020-03-13
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationOTHER HEALTH CARE PROFESSIONAL
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactSCOT HILDEN
Manufacturer Street10810 W. COLLINS AVE
Manufacturer CityLAKEWOOD CO 80215
Manufacturer CountryUS
Manufacturer Postal80215
Manufacturer Phone3032314970
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameSPECTRA OPTIA
Generic NameSPECTRA OPTIA EXCHANGE SET
Product CodeLKN
Date Received2020-03-13
Catalog Number10225
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerTERUMO BCT
Manufacturer AddressLAKEWOOD CO 80215 US 80215


Patients

Patient NumberTreatmentOutcomeDate
101. Other 2020-03-13

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.